X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (13) 13
index medicus (12) 12
female (11) 11
humans (11) 11
aged (10) 10
cancer (10) 10
middle aged (10) 10
oncology (9) 9
chemotherapy (8) 8
adult (7) 7
clinical trials (7) 7
care and treatment (6) 6
hematology, oncology and palliative medicine (6) 6
metastasis (6) 6
survival (6) 6
aged, 80 and over (5) 5
cancer therapies (5) 5
fluorouracil - administration & dosage (5) 5
irinotecan (5) 5
kaplan-meier estimate (5) 5
adenocarcinoma (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
bevacizumab (4) 4
carcinoma (4) 4
deoxycytidine - administration & dosage (4) 4
deoxycytidine - analogs & derivatives (4) 4
disease-free survival (4) 4
leucovorin (4) 4
metastases (4) 4
product development (4) 4
stomach cancer (4) 4
treatment outcome (4) 4
1st-line therapy (3) 3
2nd-line chemotherapy (3) 3
adenocarcinoma - drug therapy (3) 3
analysis (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antibodies, monoclonal, humanized - administration & dosage (3) 3
antineoplastic agents - therapeutic use (3) 3
docetaxel (3) 3
drug dosages (3) 3
drug therapy (3) 3
fluorouracil (3) 3
fluorouracil - analogs & derivatives (3) 3
folinic acid (3) 3
iii trial (3) 3
leucovorin - administration & dosage (3) 3
liver (3) 3
neutropenia (3) 3
paclitaxel (3) 3
pancreatic cancer (3) 3
prognosis (3) 3
stomach neoplasms - drug therapy (3) 3
stomach neoplasms - pathology (3) 3
1st-line treatment (2) 2
5-fluorouracil (2) 2
abridged index medicus (2) 2
adenocarcinoma - mortality (2) 2
adenocarcinoma - secondary (2) 2
anemia (2) 2
angiogenesis (2) 2
animals (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
camptothecin - administration & dosage (2) 2
camptothecin - analogs & derivatives (2) 2
capecitabine (2) 2
cetuximab (2) 2
clinical-trials (2) 2
colorectal cancer (2) 2
colorectal neoplasms - drug therapy (2) 2
colorectal neoplasms - pathology (2) 2
double-blind method (2) 2
drug administration schedule (2) 2
endothelial growth factors (2) 2
esophageal cancer (2) 2
esophagogastric junction - pathology (2) 2
folfiri (2) 2
gastric cancer (2) 2
gastric-cancer (2) 2
gemcitabine (2) 2
hypertension (2) 2
intention to treat analysis (2) 2
internal medicine (2) 2
medical colleges (2) 2
medical prognosis (2) 2
medical research (2) 2
medical treatment (2) 2
medicine (2) 2
medicine, experimental (2) 2
medicine, general & internal (2) 2
metastatic colorectal-cancer (2) 2
monoclonal antibodies (2) 2
motivation (2) 2
multicenter (2) 2
neoplasm metastasis (2) 2
organoplatinum compounds - administration & dosage (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10064, pp. 56 - 66
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10018, pp. 545 - 557
Summary Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated... 
Internal Medicine | PLUS GEMCITABINE | SURVIVAL | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | ADENOCARCINOMA | 2ND-LINE CHEMOTHERAPY | OXALIPLATIN | PEP02 | DOCETAXEL | CARCINOMA | FOLFIRI | Leucovorin - administration & dosage | Humans | Middle Aged | Male | Fatigue - chemically induced | Diarrhea - chemically induced | Pancreatic Neoplasms - drug therapy | Neoplasm Metastasis | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Camptothecin - administration & dosage | Carcinoma, Pancreatic Ductal - mortality | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Neutropenia - chemically induced | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Pancreatic Ductal - drug therapy | Irinotecan | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Liposomes | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Pancreatic cancer | Leucovorin | Product development | Research institutes | Metastasis | Antineoplastic agents | Analysis | Antigens | Chemotherapy | Medical prognosis | Clinical trials | Drug dosages | Cancer therapies | Tumors | Adenocarcinoma | Slopes | Therapy | Gemcitabine | Toxicity | Metastases | Nanoparticles | Randomization | Motivation | Vomiting | Safety management | Toxic diseases | Neutropenia | Folinic acid | Lymphatic system | Medical treatment | Diarrhea | FDA approval | Survival | Patients | Acids | Equivalence | Interactive systems
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1224 - 1235
Summary Background VEGFR-2 has a role in gastric cancer pathogenesis and progression. We assessed whether ramucirumab, a monoclonal antibody VEGFR-2... 
Hematology, Oncology and Palliative Medicine | SUPPORTIVE CARE | ONCOLOGY | BEVACIZUMAB | CLINICAL-TRIALS | GROWTH | 2ND-LINE CHEMOTHERAPY | OPEN-LABEL | 1ST-LINE THERAPY | COMBINATION | CANCER | III TRIAL | Confidence Intervals | Adenocarcinoma - pathology | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Esophageal Neoplasms - mortality | Adult | Female | Remission Induction - methods | Paclitaxel - administration & dosage | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Esophagogastric Junction - pathology | Paclitaxel - adverse effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Hospitals | Clinical trials | Monoclonal antibodies | Product development | Antineoplastic agents | Vascular endothelial growth factor | Esophageal cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 490 - 499
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 12, pp. 1225 - 1233
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2008, Volume 9, Issue 2, pp. 132 - 138
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 499 - 508
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 640 - 653
Summary Background Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | SUPPORTIVE CARE | WEEKLY PACLITAXEL | ONCOLOGY | 2ND-LINE CHEMOTHERAPY | IRINOTECAN | LEVEL | PLUS PACLITAXEL | HER2 | CANCER | DOCETAXEL | Follow-Up Studies | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Stomach Neoplasms - chemistry | Adenocarcinoma - chemistry | Taxoids - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Stomach Neoplasms - drug therapy | Maytansine - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Esophagogastric Junction | Gastrointestinal Hemorrhage - chemically induced | Retreatment | Intention to Treat Analysis | Bridged-Ring Compounds - adverse effects | Aged | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma | Medical research | Chemotherapy | Clinical trials | Medicine, Experimental | Metastasis | Esophageal cancer | Cancer | Analysis
Journal Article